Have you been paying attention to the news recently? If you have, you’ll undoubtedly have heard of cannabidiol or CBD. It’s a chemical extracted from the hemp plant, and going by the anecdotal evidence and some research findings, it’s a potent and versatile medicine. Users claim cannabidiol gave them relief from a plethora of conditions, ranging from high blood pressure and chronic pain to anxiety and insomnia.
Last year, the FDA approved a CBD-derived drug to treat seizures caused by two rare and hard to treat pediatric epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome.
Also, a recent poll by Gallup found that 14% of Americans who use CBD do so for its pain-relieving properties. The chemical is a powerful anti-inflammatory, and it’s able to help with a wide variety of inflammatory issues. Let’s look at a few of them.
Arthritis is a condition that’s common among the elderly, and it brings with it lots of pain and immobility. More than 50 million Americans suffer from the condition, with the two most common types being rheumatoid arthritis and osteoarthritis. Several studies have found that cannabidiol can make these conditions more manageable by reducing inflammation of the brain, which is one of the cases of arthritis.
By attaching itself to receptors that manage pain and inflammation, it affects how they respond to the signals they receive, thus helping to reduce pain and inflammation.
Multiple Sclerosis, or MS is a condition where the body’s immune system starts attacking the body, destroying the protective sheets around nerve fibers until the nerves are destroyed and can’t send signals. Although the exact cause isn’t known, early chronic inflammation has been shown to be partly responsible.
As we’ve seen, CBD is a powerful anti-inflammatory, and it may help suppress these inflammatory responses that lead to MS. A 2017 survey by the National Multiple Sclerosis Society found that at least 66% of MS patients were using cannabis to manage their symptoms.
Epilepsy patients can also use CBD to help manage their symptoms. Research has proven that inflammation is both a cause and consequence of epilepsy, and seizures are most often associated with inflammation of the brain. CBD is a proven anti-inflammatory, and last year, the FDA approved Epidiolex, a cannabis-based drug to treat seizures caused by two rare and hard to treat pediatric epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome.
CBD has shown a lot of promise as a natural alternative to pain relievers and anti-seizure medication. However, make sure you consult your doctor before using CBD, especially if you’re using other drugs. Experts say this is the same advice provided by various CBD companies, such as Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), to their customers, and it is sound advice to follow.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.